Assessing cell-free DNA in patients with mature B-cell lymphoma
Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
This study is testing if using blood samples to check for tumor DNA can help doctors better track treatment progress in patients with mature B-cell lymphoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 320 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT04088422 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of plasma cell-free DNA as a tool for early and dynamic assessment of treatment outcomes in patients with mature B-cell lymphoma. By collecting peripheral blood samples, the study seeks to determine if this method can provide accessible tumor DNA for tracking clonal evolution of the tumor. The findings could enhance monitoring strategies and treatment personalization for affected patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a documented diagnosis of mature B-cell tumors.
Not a fit: Patients who have undergone chemotherapy prior to the study or those with other tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring of treatment responses and better management of mature B-cell lymphoma.
How similar studies have performed: While the use of cell-free DNA in cancer monitoring is gaining traction, this specific approach in mature B-cell lymphoma is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * 18 years or older Exclusion Criteria: * Chemotherapy before * Other tumors
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Weili Zhao, MD，PhD — Ruijin Hospital
- Study coordinator: Weili Zhao, MD，PhD
- Email: zhao.weili@yahoo.com
- Phone: 64370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.